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Materials
Chemicals. AlexaFluor488-maleimide was purchased from ThermoFisher (Cat # A10254). Glycans were purchased from Carbosynth (San Diego, CA). All flavonoid compounds were purchased as lyophilized powders and dissolved in DMSO to 20 mg/mL and stored at -20°C until use. Baicalin (≥99% purity), isoquercitrin (quercitrin-3-beta-glucoside, ≥90% purity), luteolin-7-glucoside (≥98% purity), and quercetin (≥95% purity) were purchased from Sigma. Hyperoside (Quercetin-3-galactoside; Hyperin, ≥98% purity) was purchased from Indofine Chemicals Company, kaempferol (≥99% purity) was purchased from MP Biochemical, and rutin (≥97% purity) was purchased from Acros organics. Zanamivir (≥98% purity, Sigma) was dissolved in DMSO to 10 mg/mL stock. Oseltamivir carboxylate 10 mg/Ll in DMSO stock was a kind gift from Dr. Robert T Schooley, UC San Diego. The sialidase reporter molecule 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (4MU-NANA) was purchased from Sigma-Aldrich. Flavonoid toxicity was tested by incubating monolayer of MDCK with the flavonoid compounds at a concentration range between 0.78-800 µg/mL for 24 hr. Following incubation cells were evaluated under the microscope.
Biological experiments. Madin-Darby Canine Kidney (MDCK) cells (ATCC CCL-34) were cultured in Dulbeco's modified Eagle's medium (DMEM, Cellgro) supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, 100 U/ml streptomycin. Influenza virus strain A/PR/8/34 (H1N1) (ATCC VR-1469) was purchased from ATCC and propagated in MDCK cells that were transferred to DMEM medium supplemented with 0.2% BSA fraction V (EMD), 25mM HEPES buffer (Gibco), 2 µg/ml TPCK-trypsin (Worthington Corporation), and 1% penicillin/streptomycin ("DMEM-TPCK" media). Virus titers were determined by the hemagglutination test, and the 50% tissue culture infective dose (TCID 50 ) was determined in MDCK cells using the Spearman-Karber method.
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Experimental Procedures
Glycopolymer synthesis and characterization. The synthesis of the AlexaFluor488-appended polymer backbones (4) initiated with DPPE or azido-tetraethylene glycol groups has previously been described. 2, 3 Briefly, the Boc-protected (N-methylaminooxypropyl)acrylamide monomer (1) was subjected to RAFT (Reversible Addition-Fragmentation chain Transfer) polymerization 4 in the presence of a lipid or azide chain transfer agent. After successful polymerization, polymer backbone (2) molecular weights and dispersity indices were determined using size-exclusion chromatography (5 µm mixed bed, 7.8 mm I.D. x 30 cm TSK gel column from Tosoh Bioscience, 80°C, DMF + 0.2 % LiBr). Both lipid and azide polymer backbones were synthesized with low dispersity indices ~1.2. Then, the polymers were equipped with an AlexaFluor 488 (AF488) fluorophore by deprotection of the trithiocarbonyl group with n-butylamine and conjugation of the resulting free thiol with AF488-maleimide. The fluorophore conjugated polymer backbone was then subjected to sidechain Boc deprotection (via TMSCl/PhOH/DCM) and ligated to glycans (1.1 eq. relative to polymer side chain) in NaOAc buffer (pH 4.5). The glycopolymers were purified by dialyzing against deuterated phosphate buffer solutions (0.1 M Na 3 PO 4 , 0.15 M NaCl, pD = 7.4) using spin filters (10K MWCO, Millipore). Glycan ligation efficiencies were determined using 1 H NMR in deuterated phosphate buffer and polymer concentrations were calculated using the absorbance of the appended AF488 fluorophore. Following an additional 10 min fixation with 4% glutaraldehyde, the grids were washed with doubly-distilled (MilliQ) water 7 times and negative stained with 0.5% uranyl acetate for 1 min. Samples were examined with a Philips CM10 transmission electron microscope equipped with Gatan MultiScan digital camera model 794. Preparation of human salivary mucins. Human salivary mucins (HSM) were produced as previously described with slight modifications. 5, 6 Briefly, human saliva was collected from healthy human donors into tubes and placed on ice, with the approval of the UC San Diego Human Research Protections Program (protocol #080011). Saliva samples were centrifuged 5 min at 10,000 xg, and the pellet was discarded. One percent penicillin/streptomycin was added to the clear supernatant. Mucins were precipitated by adjusting the pH of the preparation to 3.5 with 50 mM hydrochloric acid (HCl), stirring over night at 4°C, and collecting at 800 xg for 10 min. The pellet was washed and re-suspended with MilliQ water, adjusted to pH 7.0 and boiled for 10 min to inhibit protease and glycosidase activity. Mucins were dialyzed against water in a 10,000 MWCO Slide-ALyzer dialysis device (Thermo Scientific), and stored in aliquots at -80°C. Sialic acid (Sia) content was determined by 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride-high performance liquid chromatography analysis (DMB-HPLC) according to a published protocol. 7 The purity of the mucins was determined by analysis of monosaccharide composition using high performance anion exchange chromatography with Pulsed Amperometric Detection (HPAEC-PAD). In addition, amino acid content was determined by Gas Chromatography Mass Spectrometry (GC-MS), 8 both performed at the UC San Diego Glycotechnology Core Resource.
Infection inhibition assay with mucins and glycopolymers. A monolayer of MDCK cells in 96-
well plates were washed with PBS, and incubated with 50 µL HSM (30 and 60 pmol/µL, resulting in 1500 or 3000 pmol/well; see Fig. S8 below) 2+ . Virus was diluted in DMEM-TPCK media to 10 6.5 TCID 50 /mL, and aliquoted into vials containing 0.1 mg/mL flavonoid compounds, 1 µM oseltamivir/zanamavir, or DMSO control. The cells were inoculated with 50 µL of virus/compound mixture for 1 hr at 37°C, washed five times with PBS, and fresh DMEM-TPCK media was added. Following 24 hr incubation at 37°C, NA activity in the cultured cells media was measured using 4MU-NANA reporter by incubating 40 µL cultured media with 1 nmol 4MU-NANA for 1hr at 37°C. The reaction was stopped and 4MU-NANA cleavage was measured. Haemagglutination inhibition (HAI) by lipidated glycopolymers (adapted from World Health Organization manual 9 ) 3'sialylactose (P1) Lactose (P5) glycopolymers was serially diluted (twofold each time) across 8 rows of a V-well 96-well plate to generate 25 µL 2X glycopolymer solutions in each well beginning with 100 nM of each. Then, 25 µL of the influenza virus (8HAU/25µL), pre-treated with or without neuraminidase inhibitors (Oseltamivir at 1µM and 100µM, Isoquercitirin at 1.5mM and 3.0mM) were then added to each condition. The plate was then placed at 37C for 35 minutes to allow the virus to engage the mucin mimetic polymers. Following, this incubation, 50 µL of 1:6 diluted guinea pig red blood cells (Lonza, 30-957J) were added to every well and allowed to settle at RT for 1 hour to determine hemagglutination efficacy of the virus bearing its polymer during an NAI treatment. Table S6 . Inhibition of haemagglutination by glycopolymers with Oseltamivir (Osel.) #1 (100µM) 
